Novelties in Evaluation and Monitoring of Human Immunodeficiency Virus-1 Infection: Is Standard Virological Suppression Enough for Measuring Antiretroviral Treatment Success?

被引：6
作者：
Svicher, Valentina [1 ]
Marchetti, Giulia [2 ]
Ammassari, Adrianna [3 ]
Ceccherini-Silberstein, Francesca [1 ]
Sarmati, Loredana [4 ]
机构：
[1] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy
[2] Univ Milan, Dept Hlth Sci, Clin Infect Dis, ASST Santi Paolo & Carlo, Milan, Italy
[3] INMI L Spallanzani, HIV AIDS Dept, Rome, Italy
[4] Univ Hosp Tor Vergata, Dept Syst Med, Clin Infect Dis, Rome, Italy
来源：
AIDS REVIEWS | 2017年 / 19卷 / 03期
关键词：
HIV-DNA; Residual viremia; Low level viremia; Genotypic resistance testin; Inflammation; Immune-activation; VIREMIA COPY-YEARS; LOW-LEVEL VIREMIA; T-CELL-ACTIVATION; PERSISTENT HIV-1 REPLICATION; SYSTEMIC IMMUNE ACTIVATION; HIV-1-INFECTED PATIENTS; DRUG-RESISTANCE; VIRAL LOAD; DARUNAVIR/RITONAVIR MONOTHERAPY; TREATMENT-NAIVE;
D O I：
10.24875/AIDSRev.M17000003
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The high potency and tolerability of the currently available antiretroviral drugs has modified HIV-1 infection from a life-threatening disease to a chronic illness. Nevertheless, some issues still remain open to optimize the management of HIV-1 infected patients in term of maintenance of virological suppression over time, identifying patients that could benefit from simplification therapy, and reducing co-mordibities driven by chronic inflammation. The availability of robust and affordable virological and immunological markers can help in solving these issues by providing information on the burden of HIV-1 reservoir in all the anatomical compartments in which the virus replicates as well as on persistent inflammation, immune activation and senescence despite successful virological suppression. In this light, this review is aimed at providing new insights (arising from a two-day Italian expert meeting hold in Rome in March 2016) in evaluation and monitoring of HIV-1 infection from a virological, immunological and clinical perspective. Particular attention has been focused on role of novel parameters (such as total HIV-1 DNA, residual viremia, and immunological markers) in optimizing treatment strategies, enhancing medical adherence, and individualizing monitoring.
引用
收藏
页码：119 / 133
页数：15
相关论文
共 50 条
[31]   Human Immunodeficiency Virus Viral Load Monitoring and Rate of Virologic Suppression Among Patients Receiving Antiretroviral Therapy in Democratic Republic of the Congo, 2013-2020 [J].
Ngongo, Nadine Mayasi ;
Ntambwe, Erick Kamangu ;
Nani-Tuma, Hippolyte Situakibanza ;
Mambimbi, Marcel Mbula ;
Ndona, Madone Mandina ;
Mashi, Murielle Longokolo ;
Izizag, Ben Bepouka ;
Lukiana, Tuna ;
Ossam, Jerome Odio ;
Sonzi, Donatien Mangala ;
Maes, Nathalie ;
Moutschen, Michel ;
El Moussaoui, Majdouline ;
Darcis, Gilles .
OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (06)
[32]   High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity Is Improved by Treatment With Antiretroviral Therapy in Acute Human Immunodeficiency Virus Infection [J].
Lo, Janet ;
Rosenberg, Eric S. ;
Fitzgerald, Michael L. ;
Bazner, Suzane B. ;
Ihenachor, Ezinne J. ;
Hawxhurst, Victoria ;
Borkowska, Alison H. ;
Wei, Jeffrey ;
Zimmerman, Chloe O. ;
Burdo, Tricia H. ;
Williams, Kenneth C. ;
Freeman, Mason W. ;
Grinspoon, Steven K. .
OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (03)
[33]   Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I [J].
Gregson, J. ;
Rhee, S. Y. ;
Datir, R. ;
Pillay, D. ;
Perno, C. F. ;
Derache, A. ;
Shafer, R. S. ;
Gupta, R. K. .
JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (07) :1108-1116
[34]   APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection [J].
Gourraud, P. A. ;
Karaouni, A. ;
Woo, J. M. ;
Schmidt, T. ;
Oksenberg, J. R. ;
Hecht, F. M. ;
Liegler, T. J. ;
Barbour, J. D. .
HUMAN IMMUNOLOGY, 2011, 72 (03) :207-212
[35]   Discontinuing combination antiretroviral therapy during the first trimester of pregnancy:: Insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count [J].
Bucceri, AM ;
Somigliana, E ;
Matrone, R ;
Uberti-Foppa, C ;
Viganò, P ;
Vignali, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (02) :545-551
[36]   Long-term Use of Proton Pump Inhibitors Is Associated With Increased Microbial Product Translocation, Innate Immune Activation, and Reduced Immunologic Recovery in Patients With Chronic Human Immunodeficiency Virus-1 Infection [J].
Serpa, J. A. ;
Rueda, A. M. ;
Somasunderam, A. ;
Utay, N. S. ;
Lewis, D. ;
Couturier, J. P. ;
Breaux, K. G. ;
Rodriguez-Barradas, M. .
CLINICAL INFECTIOUS DISEASES, 2017, 65 (10) :1638-1643
[37]   Asymptomatic Human Immunodeficiency Virus-1 Infection with High CD4+ T Cell Count Does Not Alter Iron Metabolism or Hepcidin Levels: The Pilot Study [J].
Szymczak, Aleksandra ;
Zalewska, Malgorzata ;
Rymer, Weronika ;
Jankowska, Ewa A. .
INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) :265-275
[38]   Asymptomatic Human Immunodeficiency Virus-1 Infection with High CD4+ T Cell Count Does Not Alter Iron Metabolism or Hepcidin Levels: The Pilot Study [J].
Aleksandra Szymczak ;
Malgorzata Zalewska ;
Weronika Rymer ;
Ewa A. Jankowska .
Infectious Diseases and Therapy, 2022, 11 :265-275
[39]   Human T cell lymphotropic virus type 1 (HTLV-1) infection increases the CD4 count in human immunodeficiency virus type 1 (HIV-1) infected patients submitted to antiretroviral therapy (ARV) [J].
Filipe FA Rego ;
Luiz CJ Alcantara ;
Tulio de Oliveira .
Retrovirology, 11 (Suppl 1)
[40]   The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro [J].
Drogan, Daniel ;
Rauch, Pia ;
Hoffmann, Daniel ;
Walter, Hauke ;
Metzner, Karin J. .
ANTIVIRAL RESEARCH, 2010, 86 (03) :312-315
12345